About
Zetagen is a private, clinical-stage biopharmaceutical company founded in 2015, focused on pioneering treatments for metastatic bone cancers and osteologic interventions. Its multi-patented ZetaMet™ technology, licensed exclusively from the State University of New York in 2016, is a first-of-its-kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen’s drug-eluting implant therapy has successfully completed preclinical trials and is preparing for its first human clinical trial. The company’s pipeline also includes additional oncologic treatments for Skeletal Related Events (SREs), such as ZetaMet Flowable™, along with osteologic solutions including ZetaFuse™, ZetaSet™, ZetaDent™, and ZetaBase™, supported by Series A funding, private and angel investors, and NIH Phase I and II research grants.
SyracuseHealth Care